Literature DB >> 21084304

Cell-based analysis of structure-function activity of threonine aspartase 1.

Carolin Bier1, Shirley K Knauer, Alexander Klapthor, Andrea Schweitzer, Alexander Rekik, Oliver H Krämer, Rolf Marschalek, Roland H Stauber.   

Abstract

Taspase1 is a threonine protease responsible for cleaving intracellular substrates. As such, (de)regulated Taspase1 function is expected not only to be vital for ordered development but may also be relevant for disease. However, the full repertoires of Taspase1 targets as well as the exact biochemical requirements for its efficient and substrate-specific cleavage are not yet resolved. Also, no cellular assays for this protease are currently available, hampering the exploitation of the (patho)biological relevance of Taspase1. Here, we developed highly efficient cell-based translocation biosensor assays to probe Taspase1 trans-cleavage in vivo. These modular sensors harbor variations of Taspase1 cleavage sites and localize to the cytoplasm. Expression of Taspase1 but not of inactive Taspase1 mutants or of unrelated proteases triggers proteolytic cleavage and nuclear accumulation of the biosensors. Employing our assay combined with scanning mutagenesis, we identified the sequence and spatial requirements for efficient Taspase1 processing in liquid and solid tumor cell lines. Collectively, our results defined an improved Taspase1 consensus recognition sequence, Q(3)(F/I/L/V)(2)D(1)↓G(1)'X(2)'D(3)'D(4)', allowing the first genome-wide bioinformatic identification of the human Taspase1 degradome. Among the 27 most likely Taspase1 targets are cytoplasmic but also nuclear proteins, such as the upstream stimulatory factor 2 (USF2) or the nuclear RNA export factors 2/5 (NXF2/5). Cleavage site recognition and proteolytic processing of selected targets were verified in the context of the biosensor and for the full-length proteins. We provide novel mechanistic insights into the function and bona fide targets of Taspase1 allowing for a focused investigation of the (patho)biological relevance of this type 2 asparaginase.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084304      PMCID: PMC3024795          DOI: 10.1074/jbc.M110.161646

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Nuclear export factor family protein participates in cytoplasmic mRNA trafficking.

Authors:  Irina Tretyakova; Andrei S Zolotukhin; Wei Tan; Jenifer Bear; Friedrich Propst; Gordon Ruthel; Barbara K Felber
Journal:  J Biol Chem       Date:  2005-07-12       Impact factor: 5.157

2.  NXF5, a novel member of the nuclear RNA export factor family, is lost in a male patient with a syndromic form of mental retardation.

Authors:  L Jun; S Frints; H Duhamel; A Herold; J Abad-Rodrigues; C Dotti; E Izaurralde; P Marynen; G Froyen
Journal:  Curr Biol       Date:  2001-09-18       Impact factor: 10.834

3.  Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker.

Authors:  K Engels; S K Knauer; D Metzler; C Simf; O Struschka; C Bier; W Mann; A F Kovács; R H Stauber
Journal:  J Pathol       Date:  2007-04       Impact factor: 7.996

4.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

5.  Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.

Authors:  Jason A Dubovsky; Douglas G McNeel; John J Powers; John Gordon; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Clin Cancer Res       Date:  2009-04-28       Impact factor: 12.531

6.  Interaction of AF4 wild-type and AF4.MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology?

Authors:  Adelheid Bursen; Sven Moritz; Anne Gaussmann; Sören Moritz; Theo Dingermann; Rolf Marschalek
Journal:  Oncogene       Date:  2004-08-19       Impact factor: 9.867

7.  Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.

Authors:  Verena Fetz; Carolin Bier; Negusse Habtemichael; Robert Schuon; Andrea Schweitzer; Martin Kunkel; Knut Engels; Adorján F Kovács; Sandra Schneider; Wolf Mann; Roland H Stauber; Shirley K Knauer
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

8.  Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions.

Authors:  Han Liu; Emily H-Y Cheng; James J-D Hsieh
Journal:  Genes Dev       Date:  2007-10-01       Impact factor: 11.361

9.  Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties.

Authors:  Akihiko Yokoyama; Issay Kitabayashi; Paul M Ayton; Michael L Cleary; Misao Ohki
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

10.  Are MYO1C and MYO1F associated with hearing loss?

Authors:  Cristina Zadro; Maria Stella Alemanno; Emanuele Bellacchio; Romina Ficarella; Francesca Donaudy; Salvatore Melchionda; Leopoldo Zelante; Raquel Rabionet; Nele Hilgert; Xavier Estivill; Guy Van Camp; Paolo Gasparini; Massimo Carella
Journal:  Biochim Biophys Acta       Date:  2008-11-05
View more
  14 in total

1.  "Targeting Taspase1 for Cancer Therapy"-Response.

Authors:  David Y Chen; Shugaku Takeda; Toshinao Oyama; James J Hsieh
Journal:  Cancer Res       Date:  2012-06-01       Impact factor: 12.701

2.  Development and Use of Assay Conditions Suited to Screening for and Profiling of SET-Domain-Targeted Inhibitors of the MLL/SET1 Family of Lysine Methyltransferases.

Authors:  Joseph J Ferry; Robert F Smith; Natalie Denney; Colin P Walsh; Lauren McCauley; Jie Qian; Haiching Ma; Kurumi Y Horiuchi; Konrad T Howitz
Journal:  Assay Drug Dev Technol       Date:  2015-05       Impact factor: 1.738

3.  Impact of Secretion-Active Osteoblast-Specific Factor 2 in Promoting Progression and Metastasis of Head and Neck Cancer.

Authors:  Désirée Gül; Andrea Schweitzer; Aya Khamis; Shirley K Knauer; Guo-Bin Ding; Laura Freudelsperger; Ioannis Karampinis; Sebastian Strieth; Jan Hagemann; Roland H Stauber
Journal:  Cancers (Basel)       Date:  2022-05-09       Impact factor: 6.575

4.  The Taspase1/Myosin1f-axis regulates filopodia dynamics.

Authors:  Astrid Hensel; Paul Stahl; Lisa Moews; Lena König; Rutuja Patwardhan; Alexander Höing; Nina Schulze; Perihan Nalbant; Roland H Stauber; Shirley K Knauer
Journal:  iScience       Date:  2022-05-05

Review 5.  Taspase1: a 'misunderstood' protease with translational cancer relevance.

Authors:  D Wünsch; A Hahlbrock; S Jung; T Schirmeister; J van den Boom; O Schilling; S K Knauer; R H Stauber
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

6.  Free glycine accelerates the autoproteolytic activation of human asparaginase.

Authors:  Ying Su; Christos S Karamitros; Julian Nomme; Theresa McSorley; Manfred Konrad; Arnon Lavie
Journal:  Chem Biol       Date:  2013-04-18

7.  A Bivalent Supramolecular GCP Ligand Enables Blocking of the Taspase1/Importin α Interaction.

Authors:  Alexander Höing; Alexander Zimmermann; Lisa Moews; Matthias Killa; Marius Heimann; Astrid Hensel; Jens Voskuhl; Shirley K Knauer
Journal:  ChemMedChem       Date:  2021-10-19       Impact factor: 3.540

8.  Sumoylation of HDAC2 promotes NF-κB-dependent gene expression.

Authors:  Tobias Wagner; Nicole Kiweler; Katharina Wolff; Shirley K Knauer; André Brandl; Peter Hemmerich; Jan-Hermen Dannenberg; Thorsten Heinzel; Günter Schneider; Oliver H Krämer
Journal:  Oncotarget       Date:  2015-03-30

9.  Overexpression of the catalytically impaired Taspase1 T234V or Taspase1 D233A variants does not have a dominant negative effect in T(4;11) leukemia cells.

Authors:  Carolin Bier; Rouven Hecht; Lena Kunst; Sabine Scheiding; Désirée Wünsch; Dorothée Goesswein; Günter Schneider; Oliver H Krämer; Shirley K Knauer; Roland H Stauber
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

10.  The protein corona protects against size- and dose-dependent toxicity of amorphous silica nanoparticles.

Authors:  Dominic Docter; Christoph Bantz; Dana Westmeier; Hajo J Galla; Qiangbin Wang; James C Kirkpatrick; Peter Nielsen; Michael Maskos; Roland H Stauber
Journal:  Beilstein J Nanotechnol       Date:  2014-08-27       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.